Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

CEConversations

CEConversations artwork

MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

Oct 1, 20251 hr 5 minAudio

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively impacts patients’ clinical outcomes and quality of life. These challenges necessitate an integrated, longitudinal management approach that encompasses the totality of the interprofessional, multidisciplinary team of clinicians in pediatric and adult care settings. In this CEC Oncology live, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan. Learn More: https://www.ceconcepts.com/activity/save-the-date-mek-inhibitors-in-neurofibromatosis-type-1-nursing-contributions-to-nf1-pn-management/

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Webcast Finding the Right Rhythm: Supporting Pediatric Oncology Nurses in Longitudinal NF1 Management

    Oct 28, 202656 minAudio

    In this CE Concepts recorded symposium, faculty will apply NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs in pediatric patients. Learners will be shown how to incorporate MEK...

    Credit the people on this episode

  2. Webcast: Rare, Complex, and Under-Recognized: Supporting Oncology Nurses in the Care of Patients with NF1

    Aug 6, 202652 minAudio

    Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in...

    Credit the people on this episode

  3. Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors

    Jul 1, 202632 minAudio

    Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of...

    Credit the people on this episode

  4. Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN

    Jul 1, 20261 hr 4 minAudio

    Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform...

    Credit the people on this episode

  5. Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies

    Jul 1, 20261 hr 5 minAudio

    Despite significant advances in the management of advanced or recurrent endometrial cancer (EC) - including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies - delivering timely,...

    Credit the people on this episode